Accessibility Menu
Cardiol Therapeutics logo

Cardiol Therapeutics

(TSX) CRDL

Current PriceCA$1.69
Market CapCA$194.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-59%
5 Year-37%
1 Year+5%
1 Month+13%
Cardiol Therapeutics last closing stock price
MetricPriceDate
Last closeCAD 1.692026-07-17
Cardiol Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+17.36%CAD 1.442026-07-10
1 month+13.42%CAD 1.492026-06-17
3 month-17.96%CAD 2.062026-04-17
Year to date+29.01%CAD 1.312025-12-31
1 year+4.97%CAD 1.612025-07-17
3 year+57.94%CAD 1.072023-07-18
5 year-37.41%CAD 2.702021-07-16
Since inception-59.28%CAD 4.152018-12-20

Cardiol Therapeutics Financials at a Glance

Market Cap

CA$194.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$36.35M

EPS (TTM)

-CA$0.39

P/E Ratio

-4.33

Dividend

CA$0.00

Beta (Volatility)

1.70 (High)

Price

CA$1.69

Volume

112,633

Open

CA$1.74

Previous Close

CA$1.69

Daily Range

CA$1.65 - CA$1.74

52-Week Range

CA$1.23 - CA$2.33

Estimated Earnings Date

Aug 17, 2026

CRDL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cardiol Therapeutics

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing innovative treatments for cardiovascular diseases, particularly targeting fibrosis and inflammation. The company's flagship product, CardiolRx, is currently in a Phase II/III clinical trial aimed at evaluating its efficacy in patients hospitalized with COVID-19 and addressing acute myocarditis.

Products and Services
  • CardiolRx: A heart-protective therapy in clinical trials
  • Injectable formulation targeting cardiac scarring and inflammation
  • Research and development in cardiovascular disease treatments
Growth Outlook
  • Ongoing Phase II/III trial could lead to significant market opportunities
  • Expansion of product pipeline with innovative therapies in development
  • Strong focus on addressing unmet needs in cardiovascular health
Financial Highlights
  • Cash and cash equivalents of CAD 27.67 million as of March 31, 2026
  • Operating expenses of CAD 9.68 million in Q1 2026
  • Net income of CAD -10.82 million for Q1 2026, reflecting ongoing investment in R&D
Cardiol Therapeutics Inc. is positioned in the healthcare sector, specifically within the drug manufacturing industry, focusing on specialty and generic drugs. The company has made significant strides in its clinical trials, which could pave the way for future revenue streams. The current cash position provides a solid foundation for continued research and development efforts, essential for advancing its innovative therapies. The ongoing clinical trials and the development of new formulations highlight the company's commitment to addressing critical health challenges in cardiovascular care.
AI Generated • Jul 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

23

CEO

David G. Elsley, MBA

Website

www.cardiolrx.com

Headquarters

Oakville, ON L6H 0G5, CA

CRDL Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-229.16%

Return on Capital

-190.61%

Return on Assets

-115.74%

Earnings Yield

-23.09%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$194.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

115.27M

Volume

112.63K

Avg. Volume

72.93K

Financials (TTM)

Gross Profit

-CA$103.71K

Operating Income

-CA$35.59M

EBITDA

-CA$35.27M

Operating Cash Flow

-CA$24.22M

Capital Expenditure

-CA$60.13K

Free Cash Flow

-CA$24.28M

Cash & ST Invst.

CA$27.67M

Total Debt

CA$116.41K

Cardiol Therapeutics Performance Analysis

Cardiol Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 0N/A
20232023-12-31CAD 0N/A
20242024-12-31CAD 0N/A
20252025-12-31CAD 0N/A
Cardiol Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Cardiol Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.49-32.4%
20232023-12-31CAD -0.44-11.8%
20242024-12-31CAD -0.5117.4%
20252025-12-31CAD -0.39-24.1%
Cardiol Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30-20.0%
Q42025-12-3140.1%
Q12026-03-31-38.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$26.71K

-6.9%

Gross Margin

0.00%

N/A

Market Cap

CA$194.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$10.82M

N/A

Employees

18

N/A

Net Income

-CA$10.82M

-30.5%

EBITDA

-CA$9.68M

-15.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CA$27.67M

+18.8%

Total Debt

CA$116.41K

-22.7%

Accounts Receivable

CA$339.71K

-2.0%

Inventory

CA$0.00

N/A

Long Term Debt

CA$76.62K

-34.2%

Short Term Debt

CA$39.79K

-41.9%

Return on Assets

-1.16%

N/A

Return on Invested Capital

-1.47%

N/A

Free Cash Flow

-CA$7.57M

-5.6%

Operating Cash Flow

-CA$7.52M

-5.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LOVE.VCannara Biotech Inc.
CA$1.89+6.18%
RX.VBioSyent Inc.
CA$14.50+0.00%
HLS.TOHLS Therapeutics Inc.
CA$4.11-1.20%
ZEN.VZentek Ltd.
CA$0.65+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
NFLXNetflix
$68.95-0.07%
NOKNokia
$10.12-0.03%

Questions About CRDL

What is the current price of Cardiol Therapeutics?

Cardiol Therapeutics is trading at CA$1.69 per share.

What is the 52-week range for Cardiol Therapeutics?

Over the past 52 weeks, Cardiol Therapeutics has traded between CA$1.23 and CA$2.33.

How much debt does Cardiol Therapeutics have?

As of the most recent reporting period, Cardiol Therapeutics reported total debt of CA$116.41K.

How much cash does Cardiol Therapeutics have on hand?

Cardiol Therapeutics reported CA$27.67M in cash and cash equivalents in its most recent financial results.

What is Cardiol Therapeutics’s dividend yield?

Cardiol Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services